![]() |
|
![]() |
| Home | About and More Information | Transporter Data Index |
Synonyms: Oct3
Entrez Gene Link
No expression data.
| Substrate | Km (μM) | Cell System | Reference |
|---|---|---|---|
| Dopamine | 1500 | HEK293-rOCT3 | Amphoux, 2006 |
| Epinephrine | 1500 | HEK293-rOCT3 | Amphoux, 2006 |
| Histamine | 540 | HEK293-rOCT3 | Amphoux, 2006 |
| Norepinephrine | 1900 | HEK293-rOCT3 | Amphoux, 2006 |
| Serotonin | 500 | HEK293-rOCT3 | Amphoux, 2006 |
ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022
| Inhibitor | IC50 (μM) | Ki (μM) | Substrate used | Cell System | Reference |
|---|---|---|---|---|---|
| 3,4-methylenedioxymetamphetamine (MDMA) | 1.6 | N-methylpyridinium | HEK293-rOCT3 | Amphoux, 2006 | |
| Amantadine | >1000 | N-methylpyridinium | HEK293-rOCT3 | Amphoux, 2006 | |
| Cocaine | >1000 | N-methylpyridinium | HEK293-rOCT3 | Amphoux, 2006 | |
| D-amphetamine | 4.5 | N-methylpyridinium | HEK293-rOCT3 | Amphoux, 2006 | |
| Ketamine | 65.7 | N-methylpyridinium | HEK293-rOCT3 | Amphoux, 2006 | |
| Memantine | 295 | N-methylpyridinium | HEK293-rOCT3 | Amphoux, 2006 | |
| MK-801 | >1000 | N-methylpyridinium | HEK293-rOCT3 | Amphoux, 2006 | |
| Phencyclidine | 3 | N-methylpyridinium | HEK293-rOCT3 | Amphoux, 2006 |
ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022
No drug-drug interaction information.